According to the latest guidelines by the Infectious Disease Society of America (IDSA), there is no defined standard of care for Acinetobacter baumannii infections, especially the ones with carbapenem resistant phenotypes. The IDSA guidelines do not comment on the utility of cefoperazone sulbactam since this an old drug that is no longer available in the US. Despite the limitations of the data (different disease locations, dose variability, treatment duration), single agent treatment was associated with a considerable response in most cases (70% clinical cure on average). Higher quality data systematically captured and standardized through CURE ID should provide a more robust data set to inform trial design and support clinical trials.
